Health Care

Thermo Fisher’s new “Accelerator Drug Development” launch boosts time‑to‑approval by 20 %, expands global GMP capacity, and uses AI to cut costs – a game‑changer for pharma and biotech firms.

Alcon Inc’s shares fell ~14% over the past year, underperforming Swiss peers yet staying stable. Discover why the Swiss market sees cautious, moderate shifts.

Illumina’s analyst upgrades, solid earnings, and institutional backing signal strong upside, yet supply‑chain, IP and regulatory risks loom over its genomics dominance.

Demant A/S sees modest share rise on strong hearing‑care sales; Nordea hikes target to 350 kr, while BNP Paribas stays neutral, amid 3.7% short interest.

Insmed’s CFO exit and 2026 revenue outlook show a resilient, high‑value CF & COPD strategy, poised for value‑based contracts, M&A and global growth.

Biogen’s 5 Oct 2026 Form 4 reveals Chief Accounting Officer Sean Godbout’s modest share purchases, sales, RSU grants, and ESPP activity – a routine insider snapshot with no strategic impact.

Discover how Roivant Sciences’ recent insider trades and 5‑year gains highlight investor confidence and biotech growth potential.

Abbott’s FDA‑approved CardioMEMS upgrade adds a smartphone app, real‑time data, and clinician‑direct medication plans—cutting readmissions by up to 83% and boosting ROI.

ResMed’s solid earnings grow from recurring CPAP sales, expanding cloud‑based sleep‑apnea diagnostics and strong regulatory compliance—a steady play for investors and clinicians.

Explore Bristol‑Myers Squibb’s new $1 million Champions in Care grant, expanding support for underserved communities while analysts weigh its impact on share price.